Proteotyping SARS-CoV-2 virus from nasopharyngeal swabs: a proof-of-concept focused on a 3 min mass spectrometry window

Duarte Gouveia[1§], Guylaine Miotello[1§], Fabrice Gallais[1], Jean-Charles Gaillard[1], Stéphanie Debroas[1], Laurent Bellanger[1], Jean-Philippe Lavigne[2,3], Albert Sotto[4], Lucia Grenga[1], Olivier Pible[1], Jean Armengaud[1*]

[1]Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, 30200 Bagnols-sur-Cèze, France.

[2]U1047, Institut National de la Santé et de la Recherche Médicale, Université Montpellier, France

[3]VBMI, INSERM U1047, Université de Montpellier, Service de Microbiologie et Hygiène Hospitalière, CHU Nîmes, Nîmes, France.

[4]VBMI, INSERM U1047, Université de Montpellier, Service des Maladies Infectieuses et Tropicales, CHU Nîmes, Nîmes, France.

Supplementary data

Table S1. List of *m/z* values of the inclusion list.

Table S2. UNIPEPT taxonomical analysis of Swab R1, Swab R2, and simili swab 7R1-1pfu samples.

Table S3. List of peptide-to-spectrum matches (PSMs) assigned from the simili SARS-CoV-2 swabs (FDR<1%).

Table S4. List of proteins from the simili SARS-CoV-2 swabs and their spectral counts.

Table S5. List of peptide-to-spectrum matches (PSMs) assigned in the clinical samples (FDR<1%).

Table S6. List of proteins identified in the clinical samples and their spectral counts.

Table S7. Skyline report with experimental data on precursor ions from the nine swabs from COVID-19 patients.